Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products.
Join us for an expert roundtable discussion highlighting new technologies and strategies to reduce risk and execute consistently. Leverage the experience of a top CDMO for best practices including: